Literature DB >> 11812946

Unusual morphologic patterns of basal cell hyperplasia of the prostate.

Nathalie C Rioux-Leclercq1, Jonathan I Epstein.   

Abstract

The distinction of basal cell hyperplasia (BCH) from carcinoma or high-grade prostatic intraepithelial neoplasia may be difficult. We reviewed 25 cases of BCH with unusual features and identified four distinct groups: BCH with intracytoplasmic globules (five cases); BCH with calcifications (eight cases), including one with globules; BCH with squamous features (three cases); and cribriform BCH (nine cases), including two cases with globules. A total of five cases contained prominent nucleoli and/or cytologic atypia. Hyaline cytoplasmic globules have not been described in any other prostatic entity and appear diagnostic of BCH. Calcifications observed in BCH were psammomatous, differing from the fine stippled calcifications occasionally seen in areas of comedonecrosis within high-grade prostatic carcinoma. Basal cell hyperplasia with squamous features differed from squamous differentiation in carcinomas (adenosquamous carcinoma) and from benign foci of squamous differentiation seen associated with either prostatic infarcts or with hormonal therapy. Whereas cribriform prostatic intraepithelial neoplasia and cribriform cancer glands represent a single glandular unit with punched out lumina, many of the glands within a focus of cribriform BCH appeared as fused individual BCH glands. The use of cytokeratin 34betaE12 can help in difficult cases. In cribriform BCH high-molecular-weight cytokeratin shows multilayered staining of the basal cells in some of the glands and a continuous layer of immunoreactivity. Cribriform prostatic intraepithelial neoplasia demonstrates an interrupted immunoreactive single cell layer of basal cells. Recognition of the architectural and cytologic features of unusual morphologies of BCH can be used to facilitate its diagnosis and differentiation from prostatic carcinoma and high-grade prostatic intraepithelial neoplasia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812946     DOI: 10.1097/00000478-200202000-00011

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression.

Authors:  R Montironi; R Mazzucchelli; D Stramazzotti; M Scarpelli; A López Beltran; D G Bostwick
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 2.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

3.  A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate.

Authors:  Lin He; Christopher Metter; Vitaly Margulis; Payal Kapur
Journal:  Case Rep Pathol       Date:  2021-05-04

4.  Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.

Authors:  Xiaodong Sun; Xiaoying Fu; Jie Li; Changsheng Xing; Henry F Frierson; Hao Wu; Xiaokun Ding; Tongzhong Ju; Richard D Cummings; Jin-Tang Dong
Journal:  Neoplasia       Date:  2014-06-14       Impact factor: 5.715

5.  Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.

Authors:  Julian Arista-Nasr; Braulio Martinez-Benitez; Leticia Bornstein-Quevedo; Elizmara Aguilar-Ayala; Claudia Natalia Aleman-Sanchez; Raul Ortiz-Bautista
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

Review 6.  Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate.

Authors:  Kenichiro Ishii; Sanai Takahashi; Yoshiki Sugimura; Masatoshi Watanabe
Journal:  J Clin Med       Date:  2018-04-02       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.